Laurion Capital Management’s Denali Therapeutics DNLI Stock Holding History

Laurion Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-50,000	Closed	-$876K	–	964
2020 Q1	$876K	Buy	+50,000	New	+$1.04M	0.01%	514
2018 Q2	–	Sell	-118,581	Closed	-$2.33M	–	1378
2018 Q1	$2.33M	Buy	118,581 +33,581	+40%	+$690K	0.02%	590
2017 Q4	$1.33M	Buy	+85,000	New	+$1.53M	0.01%	896

Other funds holding DNLI

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Laurion Capital Management's DNLI Position: Q2 2020 in Review

Laurion Capital Management sold out of Denali Therapeutics (DNLI) in Q2 2020, closing a stake of 50,000 shares — an estimated $876K sold.

Laurion Capital Management first reported a position in DNLI in Q4 2017 and held it in 3 quarters. The position peaked at $2.33M in Q1 2018. 148 funds tracked by Wall St. Rank hold DNLI as of Q2 2020.

Laurion Capital Management reported no remaining Denali Therapeutics position as of Q2 2020 after selling out during the quarter.
Laurion Capital Management sold 50,000 Denali Therapeutics shares in Q2 2020, an estimated $876K.
Laurion Capital Management first reported a position in Denali Therapeutics in Q4 2017 and held it in 3 quarters.
Laurion Capital Management's Denali Therapeutics position peaked at $2.33M in Q1 2018.
148 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2020.

Based on Laurion Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.